Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Författare

  • Panagiotis Baliakas
  • Andreas Agathangelidis
  • Anastasia Hadzidimitriou
  • Lesley-Ann Sutton
  • Eva Minga
  • Athina Tsanousa
  • Lydia Scarfò
  • Zadie Davis
  • Xiao-Jie Yan
  • Tait Shanafelt
  • Karla Plevova
  • Yorick Sandberg
  • Fie Juhl Vojdeman
  • Myriam Boudjogra
  • Tatiana Tzenou
  • Maria Chatzouli
  • Charles C Chu
  • Silvio Veronese
  • Anne Gardiner
  • Larry Mansouri
  • Karin E Smedby
  • Lone Bredo Pedersen
  • Denis Moreno
  • Kirsten Van Lom
  • Véronique Giudicelli
  • Hana Skuhrova Francova
  • Florence Nguyen-Khac
  • Panagiotis Panagiotidis
  • Gunnar Juliusson
  • Lefteris Angelis
  • Achilles Anagnostopoulos
  • Marie-Paule Lefranc
  • Monica Facco
  • Livio Trentin
  • Mark Catherwood
  • Marco Montillo
  • Christian H Geisler
  • Anton W Langerak
  • Sarka Pospisilova
  • Nicholas Chiorazzi
  • David Oscier
  • Diane F Jelinek
  • Nikos Darzentas
  • Chrysoula Belessi
  • Frederic Davi
  • Paolo Ghia
  • Richard Rosenquist
  • Kostas Stamatopoulos

Summary, in English

An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

Avdelning/ar

  • Stamcellscentrum (SCC)
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publiceringsår

2015

Språk

Engelska

Sidor

856-859

Publikation/Tidskrift/Serie

Blood

Volym

125

Issue

5

Dokumenttyp

Artikel i tidskrift

Förlag

American Society of Hematology

Ämne

  • Hematology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1528-0020